Effect of peroxisome proliferator-activated receptor γ ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction

This publication has 29 references indexed in Scilit:

• PPAR-γ inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1
  American Journal of Physiology-Heart and Circulatory Physiology, 2006
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
  The Lancet, 2005
• Angiotensin II Regulation of Collagen Type I Expression in Cardiac Fibroblasts
  Hypertension, 2004
• Inflammatory Cytokines and Postmyocardial Infarction Remodeling
  Circulation Research, 2004
• Peroxisome proliferator activated‐receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction
  British Journal of Pharmacology, 2004
• Pioglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, Attenuates Myocardial Ischemia/Reperfusion Injury in a Rat Model
  Laboratory Investigation, 2003
• Peroxisome Proliferator-Activated Receptor-α and Receptor-γ Activators Prevent Cardiac Fibrosis in Mineralocorticoid-Dependent Hypertension
  Hypertension, 2003
• The PPARγ-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction
  Cardiovascular Research, 2003
• Pioglitazone, a Peroxisome Proliferator–Activated Receptor-γ Agonist, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction
  Circulation, 2002
• Ca²⁺‐sensitizing effect is involved in the positive inotropic effect of troglitazone
  British Journal of Pharmacology, 2001